PeptiDream - Company History

PeptiDream was founded in Chiyoda, Tokyo, in July 2006 by two men with deliberately separated jobs. Suga Hiroaki, then a professor at the University of Tokyo’s Research Center for Advanced Science and Technology, had developed flexizyme — an artificial RNA catalyst that lets unnatural amino acids be loaded into a peptide chain, and so lets vast libraries of macrocyclic peptides be built and screened. Kubota Kiichi, who had come through Nissan Motor and the drug-discovery firm JGS, took the business. The split was the point: Kubota held that when the same person runs the research and the company, the inventor’s science bends to commercial judgement. Suga stayed with the technique and its publication; Kubota decided what the company would and would not do.

The founding asset was a licence rather than a laboratory. In December 2006 the company took an exclusive licence with sublicensing rights to the flexizyme patents from the University of Tokyo, and in May 2007 the same from the State University of New York. Offices moved to Meguro in 2009 and the laboratories were consolidated into the university’s Komaba Research Campus in April 2010.

In October 2010 PeptiDream announced the Peptide Discovery Platform System (PDPS), which uses flexizyme to narrow drug candidates out of libraries on the order of a quadrillion cyclic peptides. With it came the choice that defined the company. Developing a drug end to end means years without revenue and only one or two programmes at a time; instead PeptiDream would find candidates and hand everything downstream — target selection, trials, marketing — to the pharmaceutical companies, earning upfront payments, milestones and royalties. It never sold a drug. It rented the machine that finds them.

PeptiDream listed on the Tokyo Stock Exchange’s Mothers market in June 2013, seven years after it was founded and — unusually for a Japanese biotech — already profitable. Revenue in the year to June 2014 was about $7.6M (¥800m), small in absolute terms but earned rather than raised. In the seven years to listing the company had signed licence and joint-research agreements in quick succession with Takeda Pharmaceutical, Astellas Pharma, Bristol Myers Squibb and Novartis; contract research fees, not investor money, were the pillar of its accounts.

The market rewarded it quickly. In December 2015 the shares moved from Mothers to the First Section of the Tokyo Stock Exchange, with revenue reaching roughly $39.5M (¥4bn) in the year to June 2016 — a promotion nine years after founding, an exceptional pace for a university spinout in a sector where a decade of losses is the norm.

The founders began to withdraw. Kubota became chairman in 2016, and in September 2017 Patrick Reid — an American researcher who had built out the PDPS technology as chief science officer, by way of Dartmouth Medical School, Kobe University and US discovery groups — became president. Putting a bench scientist rather than a businessman in the chair served two ends at once: it pushed the international licensing effort, and it settled the succession beyond the two founders.

The same year the company moved its head office and laboratories to the Kingskyfront district of Kawasaki, and in September 2017 set up Peptistar, a contract manufacturer of special peptide active ingredients jointly owned with Shionogi and Sekisui Chemical. It was a characteristic move: the downstream gap was real, but the plant was placed in a separate company with other people’s capital in it, so that PeptiDream itself stayed light.

More partnerships followed the same shape. The fiscal year end was moved from June to December in 2019, leaving a six-month transitional period, to fall in line with the international partners whose contracts now drove the accounts. In April 2020 PeptiDream formed PeptiGrowth with Mitsubishi Corporation for cell-culture media peptides, and in November 2020 PeptiAid with Fujitsu, Mizuho Capital, Takenaka and Kishida Chemical to pursue a COVID-19 therapy. Revenue reached about $109.6M (¥12bn) in 2020 on an operating margin close to 60%.

In September 2021 PeptiDream agreed to buy PDR Pharma, the radiopharmaceutical business of Fujifilm Toyama Chemical, for about $277.8M (¥31bn); the price was cut to roughly $168.2M (¥22bn) when sales rights were returned before the deal closed in March 2022. In April the listing moved to the new Prime Market. For the first time the company owned manufacturing and marketing approvals — it sold products, to patients, under its own name.

The scale changed at once. Consolidated revenue went from about $85.6M (¥9bn) in 2021 to $204.8M (¥27bn), then $308.3M (¥47bn) in 2024 as PDR Pharma’s actual sales carried the group. But the second pillar brought goodwill and intangible amortisation with it, and in 2025 revenue fell back to roughly $123.6M (¥19bn) and operating results turned to a loss — the discovery business is lumpy by nature, since a contract signed or a milestone reached lands in one year and not the next.

Both founders have stepped back: Suga remains a professor at the University of Tokyo and an adviser to the company, and Kubota has left the front line. Reid runs the company with externally recruited finance and operating executives. What remains from 2006 is the flexizyme licence — but it is now one of two businesses rather than the whole of one, which is what the acquisition was for.